650Indexed trials
mesh condition
Alzheimer Disease
Intelligence
Alzheimer Disease intelligence: 650 indexed trials, 133 recruiting studies, 395 sponsors across 58 countries.
133Recruiting
395Sponsors
58Countries
Leading sponsors
Avid Radiopharmaceuticals120 recruiting
Massachusetts General Hospital123 recruiting
Eli Lilly and Company92 recruiting
Hoffmann-La Roche81 recruiting
Johns Hopkins University84 recruiting
University of California, Los Angeles72 recruiting
National Institute on Aging (NIA)71 recruiting
Emory University71 recruiting
Pfizer70 recruiting
Merck Sharp & Dohme LLC71 recruiting
National Taiwan University Hospital62 recruiting
Novartis60 recruiting
Geographic activity
United States323trials
France81trials
Canada66trials
United Kingdom50trials
Spain45trials
Italy40trials
Germany37trials
Australia34trials
Sweden34trials
Japan29trials
South Korea29trials
China27trials
Leading interventions
Donepezil12trials
florbetapir F 186trials
Memantine6trials
Donanemab4trials
Flortaucipir F184trials
MRI4trials
Gantenerumab4trials
Crenezumab3trials
Magnetic Resonance Imaging (MRI)3trials
Lecanemab3trials
CAD1063trials
Bryostatin 13trials
Methodology note
This entity is derived from structured ClinicalTrials.gov conditions and/or MeSH normalization. Counts reflect the current NeuroRisk indexed corpus and are not guaranteed exhaustive global totals.